BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1

BRAF V600E inhibitor

BRAF V600E inhibitor

Associations(299)

Associations
(299)